ACADIA Pharmaceuticals マネジメント
マネジメント 基準チェック /34
ACADIA Pharmaceuticalsの CEO はCatherine Owen Adamsで、 Sep2024年に任命され、 の在任期間は 1.67年です。 の年間総報酬は$ 8.26Mで、 11.3%給与と88.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.009%を直接所有しており、その価値は$ 333.64K 。経営陣と取締役会の平均在任期間はそれぞれ1.9年と10.3年です。
主要情報
Catherine Owen Adams
最高経営責任者
US$8.3m
報酬総額
| CEO給与比率 | 11.26% |
| CEO在任期間 | 1.7yrs |
| CEOの所有権 | 0.009% |
| 経営陣の平均在職期間 | 1.9yrs |
| 取締役会の平均在任期間 | 10.3yrs |
経営陣の近況
Recent updates
ACAD: Execution Risk Around Rett Syndrome Setback Will Limit Future Upside
Analysts trimmed the fair value estimate for ACADIA Pharmaceuticals slightly to $19.64 from $19.73, as modestly higher discount rate assumptions offset slightly stronger projected revenue growth and profitability. They maintained a supportive stance following a mix of recent price target increases and reductions across the Street.
ACAD: Future Upside Will Depend On Alzheimer Psychosis Trial Outcomes
The fair value estimate for ACADIA Pharmaceuticals has increased slightly to $31.80, as analysts incorporate updated revenue growth assumptions, mixed adjustments to price targets across firms, and ongoing expectations for contributions from Nuplazid, Daybue, and the broader pipeline. Analyst Commentary Recent research coverage on ACADIA Pharmaceuticals shows a mix of optimism and caution, with several firms revising price targets after earnings updates, guidance, and pipeline commentary.
ACAD: Remlifanserin Alzheimer’s Psychosis Data Will Drive Upside From Undervalued Levels
ACADIA Pharmaceuticals' updated analyst price target moves from $37 to about $44, with analysts pointing to refreshed models that reflect recent guidance, ongoing commercial momentum in Nuplazid and Daybue, and growing attention on the remlifanserin Phase 2 program in Alzheimer's disease psychosis. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals clusters around refreshed models, updated sales assumptions for Nuplazid and Daybue, and rising interest in the remlifanserin program in Alzheimer's disease psychosis.ACAD: Trofinetide EU Setback And Execution Risks Will Likely Restrain Upside
ACADIA Pharmaceuticals' updated analyst price target reflects a modest reset in fair value to $19.73 from $20.26, as analysts balance recent target revisions across the Street with refreshed assumptions for growth, margins, and future P/E levels. Analyst Commentary Across recent research updates, views on ACADIA are mixed, with several large firms expressing confidence in the commercial trajectory of Nuplazid and Daybue, while others are more measured and focused on execution risks and how much of the current pipeline is already reflected in the share price.ACAD: Pipeline And Execution Risks Will Likely Cap Upside Despite Renewed Optimism
ACADIA Pharmaceuticals' updated fair value estimate has edged up from $19.65 to $20.26 per share, reflecting analysts' higher price targets tied to confidence in Nuplazid and Daybue, as well as underappreciated upside from the remlifanserin pipeline asset. Analyst Commentary Recent research views on ACADIA are mixed, with some firms pointing to upside tied to Nuplazid, Daybue, and the remlifanserin program, while others are more guarded.ACAD: Higher P/E Assumptions Will Rely On Successful Rett Syndrome Expansion
Analysts have nudged their fair value estimate for ACADIA Pharmaceuticals higher by about $0.47 per share, reflecting recent price target revisions and updated assumptions around revenue growth, profitability, and future P/E multiples. Analyst Commentary Recent Street research on ACADIA Pharmaceuticals has been active, with multiple firms revising price targets and updating their views on the company.ACAD: Execution Risk And Sector Capital Pressures Will Likely Constrain Upside
Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing updated assumptions around revenue growth, profitability and future P/E expectations, alongside a generally cautious but constructive view on Biotech, with potential M&A activity helping to support the sector. Analyst Commentary While the updated US$40 target signals constructive sentiment on ACADIA Pharmaceuticals, recent commentary still carries a cautious tone around how the story plays out over time.ACAD: Higher P/E Assumptions Will Support Upside If Pipeline Milestones Deliver
Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing a refreshed view on fair value, updated discount rate assumptions, and adjusted expectations for revenue growth, profit margin, and future P/E multiples. Analyst Commentary Recent commentary around ACADIA Pharmaceuticals reflects a mix of optimism on potential value creation and caution around sector level capital trends.ACAD: Expanded Neuroscience Pipeline Will Drive Upside From Undervalued Levels
Analysts have modestly increased their price target on ACADIA Pharmaceuticals from 35.00 dollars to 37.00 dollars. They cited slightly stronger long term revenue growth, improved profit margin expectations, a marginally lower discount rate, and a higher projected future price to earnings multiple.ACAD: Upcoming Neuropsychiatric Data Expected To Drive Upside Despite Recent Setback
Analysts have trimmed their price target on ACADIA Pharmaceuticals by $5 to $35 per share. This reflects a modestly higher discount rate and lower long term profit expectations, despite slightly stronger projected revenue growth and reassurance that the ACP-101 failure has only a small impact on overall valuation.Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality
Dec 04Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings
Nov 13
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 09Global Outreach And Pipeline Programs Will Expand CNS Markets
ACADIA Pharmaceuticals’ consensus price target was revised downward to $29.32 as the Phase 3 failure of ACP-101 in Prader-Willi syndrome modestly reduced pipeline value, though the impact is seen as limited given low expectations and resilience in the core business. Analyst Commentary Bearish analysts cite the Phase 3 failure of ACP-101 in Prader-Willi syndrome (PWS), which missed its primary endpoint, leading to lowered price targets based on reduced near-term pipeline value.Global Outreach And Pipeline Programs Will Expand CNS Markets
Analysts maintained their price target for ACADIA Pharmaceuticals at $29.95 as strong Daybue growth, favorable Nuplazid patent rulings, and strategic R&D focus offset near-term competitive and pipeline uncertainties. Analyst Commentary Bullish analysts are raising price targets citing strong Daybue growth in Q2, but note further acceleration is needed for material upside.Results: ACADIA Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Aug 09ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Surges 54% Yet Its Low P/S Is No Reason For Excitement
May 30ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 09ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Mar 03Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy'
Feb 13Why Investors Shouldn't Be Surprised By ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Low P/S
Jan 08Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
Nov 27Acadia Pharmaceuticals: Proving The Naysayers Wrong
Nov 11ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08
Targeted Campaigns And Pipeline Expansions Set To Revolutionize Growth In Neurological Treatment Market
Targeted and DTC campaigns for NUPLAZID aimed at Parkinson's disease psychosis are expected to notably increase patient starts, directly enhancing market share and revenue.Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Dec 31 2025 | US$8m | US$930k | US$391m |
| Sep 30 2025 | n/a | n/a | US$261m |
| Jun 30 2025 | n/a | n/a | US$222m |
| Mar 31 2025 | n/a | n/a | US$229m |
| Dec 31 2024 | US$8m | US$246k | US$226m |
報酬と市場: Catherineの 総報酬 ($USD 8.26M ) は、 US市場 ($USD 7.11M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Catherineの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Catherine Owen Adams (55 yo)
1.7yrs
在職期間
US$8,256,518
報酬
Ms. Catherine E. Owen Adams is CEO & Director of ACADIA Pharmaceuticals Inc. from September 23, 2024. She served as Director of OptiNose US, Inc. since July 2020 until September 24, 2024. She serves as Ind...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 1.7yrs | US$8.26m | 0.0087% $ 333.6k | |
| Executive VP & CFO | 4.7yrs | US$3.12m | 0.037% $ 1.4m | |
| Executive VP | 2.3yrs | US$2.93m | 0.0066% $ 254.5k | |
| Executive VP and Head of Research & Development | 2.1yrs | US$2.89m | 0.0019% $ 73.8k | |
| Executive VP & Chief Commercial Officer | 1.4yrs | US$857.02k | データなし | |
| Senior VP | less than a year | データなし | データなし | |
| Senior Vice President of Investor Relations & Corporate Communications | 2.7yrs | データなし | データなし | |
| Senior VP & Chief People Officer | 4.3yrs | データなし | データなし | |
| Senior Vice President of Finance | no data | データなし | 0.016% $ 628.1k | |
| Senior Vice President of Rare Disease Franchise | 1yr | データなし | データなし | |
| Senior VP | less than a year | データなし | データなし |
1.9yrs
平均在職期間
50yo
平均年齢
経験豊富な経営陣: ACADの経営陣は 経験豊富 とはみなされません ( 1.9年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 1.7yrs | US$8.26m | 0.0087% $ 333.6k | |
| Independent Director | 18yrs | US$395.21k | 0.0089% $ 340.2k | |
| Independent Director | 10.4yrs | US$385.05k | 0.080% $ 3.1m | |
| Member of the Scientific and Clinical Advisory Board | no data | データなし | データなし | |
| Independent Director | 10.5yrs | US$399.03k | 0.021% $ 789.9k | |
| Member of the Scientific and Clinical Advisory Board | no data | データなし | データなし | |
| Member of the Scientific and Clinical Advisory Board | no data | データなし | データなし | |
| Independent Director | 10.3yrs | US$393.94k | 0.0024% $ 91.1k | |
| Independent Chairman of the Board | 13.3yrs | US$415.54k | 0.020% $ 767.6k | |
| Independent Director | less than a year | データなし | データなし | |
| Independent Director | 3.6yrs | US$400.30k | 0.015% $ 559.3k | |
| Independent Director | 5.7yrs | US$392.67k | 0.015% $ 572.3k |
10.3yrs
平均在職期間
60.5yo
平均年齢
経験豊富なボード: ACADの 取締役会 は経験豊富で 経験豊富 です ( 10.3年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/01 13:38 |
| 終値 | 2026/05/01 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
ACADIA Pharmaceuticals Inc. 21 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。37
| アナリスト | 機関 |
|---|---|
| Joel Beatty | Baird |
| null null | Baird |
| Jack Allen | Baird |